These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 22797391)

  • 1. Update on prognostic and predictive biomarkers for pancreatic neuroendocrine tumors.
    Oberstein PE; Saif MW
    JOP; 2012 Jul; 13(4):368-71. PubMed ID: 22797391
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pancreatic neuroendocrine tumors: entering a new era.
    Oberstein PE; Remotti H; Saif MW; Libutti SK
    JOP; 2012 Mar; 13(2):169-73. PubMed ID: 22406593
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Update on novel therapies for pancreatic neuroendocrine tumors.
    Oberstein PE; Saif MW
    JOP; 2012 Jul; 13(4):372-5. PubMed ID: 22797392
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Placental growth factor supports neuroendocrine tumor growth and predicts disease prognosis in patients.
    Hilfenhaus G; Göhrig A; Pape UF; Neumann T; Jann H; Zdunek D; Hess G; Stassen JM; Wiedenmann B; Detjen K; Pavel M; Fischer C
    Endocr Relat Cancer; 2013 Jun; 20(3):305-19. PubMed ID: 23463017
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biomarkers in neuroendocrine tumors.
    Duque M; Modlin IM; Gupta A; Saif MW
    JOP; 2013 Jul; 14(4):372-6. PubMed ID: 23846930
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel agents in the treatment of unresectable neuroendocrine tumors. Highlights from the "2011 ASCO Annual Meeting". Chicago, IL, USA; June 3-7, 2011.
    Oberstein PE; Saif MW
    JOP; 2011 Jul; 12(4):358-61. PubMed ID: 21737896
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel agents in gastroenteropancreatic neuroendocrine tumors.
    Stevenson R; Libutti SK; Saif MW
    JOP; 2013 Mar; 14(2):152-4. PubMed ID: 23474560
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Chemotherapy for GI and pancreatic NETs].
    Doi T
    Gan To Kagaku Ryoho; 2013 Jul; 40(7):838-42. PubMed ID: 23863723
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and efficacy of everolimus in adult patients with neuroendocrine tumors.
    Oberstein PE; Saif MW
    Clin Med Insights Oncol; 2012; 6():41-51. PubMed ID: 22253554
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic and predictive biomarkers in gastroenteropancreatic neuroendocrine tumors.
    Stevenson R; Libutti SK; Saif MW
    JOP; 2013 Mar; 14(2):155-7. PubMed ID: 23474561
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Survival prognostic factors of gastro-enteric-pancreatic neuroendocrine tumors after primary tumor resection in a single tertiary center: Comparison of gastro-enteric and pancreatic locations.
    Russolillo N; Vigano' L; Razzore P; Langella S; Motta M; Bertuzzo F; Papotti M; Ferrero A
    Eur J Surg Oncol; 2015 Jun; 41(6):751-7. PubMed ID: 25887286
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biomarkers in pancreatic neuroendocrine tumors.
    Theochari MS; Syrigos KN; Saif MW
    JOP; 2014 Mar; 15(2):138-9. PubMed ID: 24618438
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chromogranin A and neuron-specific enolase as prognostic markers in patients with advanced pNET treated with everolimus.
    Yao JC; Pavel M; Phan AT; Kulke MH; Hoosen S; St Peter J; Cherfi A; Öberg KE
    J Clin Endocrinol Metab; 2011 Dec; 96(12):3741-9. PubMed ID: 21994954
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapy innovation for the treatment of pancreatic neuroendocrine tumors.
    Riccardi F; Rizzo M; Festino L; Ambrosio F; Molino C; Uomo G; Cartenì G
    Expert Opin Ther Targets; 2012 Apr; 16 Suppl 2():S91-102. PubMed ID: 22372544
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Everolimus: a new treatment option for advanced pancreatic neuroendocrine tumors.
    Thompson LA; Kim M; Wenger SD; O'Bryant CL
    Ann Pharmacother; 2012 Sep; 46(9):1212-9. PubMed ID: 22947595
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advances in the systemic treatment of neuroendocrine tumors in the era of molecular therapy.
    Leung R; Lang B; Wong H; Chiu J; Yat WK; Shek T; Cho WY; Yau LC; Yau T
    Anticancer Agents Med Chem; 2013 Mar; 13(3):382-8. PubMed ID: 23092266
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biomarkers in pancreatic adenocarcinoma.
    Joza N; Saif MW
    JOP; 2014 Jul; 15(4):308-9. PubMed ID: 25076328
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The up-to-date review of epidemiological pancreatic neuroendocrine tumors in Japan.
    Ito T; Lee L; Hijioka M; Kawabe K; Kato M; Nakamura K; Ueda K; Ohtsuka T; Igarashi H
    J Hepatobiliary Pancreat Sci; 2015 Aug; 22(8):574-7. PubMed ID: 25689058
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictors of long-term outcome in patients with well-differentiated gastroenteropancreatic neuroendocrine tumors after peptide receptor radionuclide therapy with 177Lu-octreotate.
    Ezziddin S; Attassi M; Yong-Hing CJ; Ahmadzadehfar H; Willinek W; Grünwald F; Guhlke S; Biersack HJ; Sabet A
    J Nucl Med; 2014 Feb; 55(2):183-90. PubMed ID: 24434296
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of 320 gastroenteropancreatic neuroendocrine tumors identifies TS expression as independent biomarker for survival.
    Lee HS; Chen M; Kim JH; Kim WH; Ahn S; Maeng K; Allegra CJ; Kaye FJ; Hochwald SN; Zajac-Kaye M
    Int J Cancer; 2014 Jul; 135(1):128-37. PubMed ID: 24347111
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.